DEENOVA
12.7.2021 08:02:13 CEST | Business Wire | Press release
Deenova today publicly disclosed that its remarkable European market success in 2020 steadily expanded to Italy during 2021, with the recent Public Tender Award won by Deenova at ASST Vimercate Hospitals for multiple D1 unit-dose robots including 6 All-In-1 Stations , 40 modules of Barcode, Fridge and/or Narcotic cabinets, and the continuous utilisation of Deenova’s world-class of full service unit-dose and multi-dose medications solutions.
Giorgio Pavesi , Managing Director of Deenova in Italy stated: “It is a confirmation of our European market momentum that started in 2020, to combine new business robot and service contracts at premier hospitals in Europe with additional purchase of technologies and complex services by previous Deenova customers, clearly showing a high level of continued satisfaction with our automation solutions amongst our existing customer base, such as Vimercate Hospital .”
ASST Vimercate Hospitals are 5 state-of-the-art acute and non acute hospitals in the territory of Brianza, where architecture, technology and organisation are all aimed at placing the patient at the centre of the logistic and diagnostic-therapeutic paths. They include: Hospital of Vimercate, Hospital Presidium of Desio, Hospital of Carate Brianza, Seregno Hospital Presidium, Presidio Ospedaliera di Giussano with approximately 900 beds.
Christophe Jaffuel , Deenova Chief Commercial Officer, stated: “These 2 latest multi-year Public Tender wins (San Camillo and ASST Vimercate ) highlight Deenova main differentiating characteristics compared to other suppliers: patient care crafted for compliance, better safety and therapy compliance, and 24/7 availability.”
Since 2004, Deenova is the undisputed leading supplier of combined mechatronics (robotic and automation) solutions for closed loop medications and medical devices traceability in the healthcare industry, anytime and anywhere.
Deenova’s unique and fully integrated solutions have and will greatly contribute to ease healthcare providers’ growing pressures to: simultaneously improve patient safety, reduce therapy errors, minimise waste and controlled substance diversion, contain costs, and diminish the gap between rising patient volume/acuity and scarce medical staff.
Deenova guarantees the simplification of all processes related to the management of medications and implantable/disposable medical devices with an expected cost savings range between 15% and 25%.
Please visit www.deenova.com for additional information.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210711005024/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Veristat Strengthens Biostatistics, Drug Development Advisory, and People Leadership to Support Growth in Complex Clinical Development23.6.2026 13:05:00 CEST | Press release
Dr. Zhaohui Su and Dr. Gil Fine deepen Veristat’s biostatistics expertise, Scott Tarrant leads Strategic Drug Development Advisory, and Clint Wolfe joins as Chief Human Resources Officer VeristatTM, a global clinical research organization (CRO) and consultancy specializing in complex studies, today announced four strategic leadership hires that advance its mission to accelerate novel therapy approvals in complex disease areas, including cell and gene therapy, oncology, and rare disease. Building on its 30-year foundation in biostatistics and its recent acquisition of the medical writing and regulatory submission business of Certara, Veristat is deepening its scientific expertise and expanding its operational leadership to meet growing client demand. Dr. Zhaohui Su and Dr. Gil Fine join Veristat’s Strategic Drug Development Advisory team in biostatistical leadership roles, collaborating with Scott Tarrant, who has been named Executive Vice President of the team. In addition, Clint Wolfe
Bacardi Takes Full Ownership of TEELING® Irish Whiskey23.6.2026 13:00:00 CEST | Press release
Irish whiskey brand joins family-owned company’s portfolio of premium brands Bacardi Limited has announced the completion of a transaction that makes the family-owned company the sole owner of the Teeling Whiskey Company and the TEELING® Irish whiskey brand. Founders Jack and Stephen Teeling will remain a part of the brand, shaping its future and driving growth for the long term as strategic advisors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260623858211/en/ Three expressions of Teeling Irish Whiskey: Single Grain, Small Batch and Single Malt Today’s announcement follows the successful relationship the two companies have enjoyed since Bacardi acquired a minority stake in the Dublin-based whiskey company in 2017. Bacardi subsequently increased its stake to become the majority shareholder in 2022. “TEELING is the perfect fit for Bacardi,” says Mahesh Madhavan, Chief Executive Officer, Bacardi Limited. “The brand stands f
Bending Spoons S.p.A. announces launch of initial public offering23.6.2026 12:15:00 CEST | Press release
Bending Spoons S.p.A. (“Bending Spoons”), a leading technology company, today announces the launch of its initial public offering (the “IPO”) of its ordinary shares. A total of 57,971,015 ordinary shares are being offered, of which 34,398,640 are being offered by Bending Spoons and 23,572,375 are being offered by certain selling shareholders (the “Selling Shareholders”). In connection with the offering, Bending Spoons and the Selling Shareholders have granted the underwriters a 30-day option to purchase up to an additional 5,244,026 ordinary shares from Bending Spoons and an additional 3,451,626 ordinary shares from the Selling Shareholders at the IPO price, less underwriting discounts and commissions. The IPO price is currently estimated to be between $26.00 and $28.00 per share. Bending Spoons has applied to list its ordinary shares on the Nasdaq Global Select Market under the ticker symbol “BSP.” Goldman Sachs International, J.P. Morgan, and Allen & Company LLC are acting as joint l
WSJ Intelligence Study: Uniquely Human Skills Deemed "Non-Replicable" in Automated Future23.6.2026 12:00:00 CEST | Press release
Philip Morris International and WSJ Intelligence reveal a "Human Premium" in the AI era, warning of cognitive atrophy risks alongside rapid corporate automation Philip Morris International (PMI) (NYSE: PM) and WSJ Intelligence, the in-house thought leadership consultancy for The Wall Street Journal's commercial sales organization, today revealed topline findings from a forthcoming study at Journal House during the Cannes Lions International Festival of Creativity. The study delivered a clear takeaway for global businesses: human cognition must be the absolute forefront of the modern corporate landscape. The findings show that uniquely human skills are vital, non-replicable, and increasingly valuable in an AI-embedded future, with creative empathy and critical thinking among the most distinctive workplace advantages. Surveying over 2,500 business professionals across the United States, United Kingdom, Italy, South Africa and Brazil, the joint initiative is the largest-scale research pro
Bitcoin Suisse Receives MiCAR License and Launches European Expansion23.6.2026 11:37:00 CEST | Press release
The Liechtenstein Financial Market Authority has granted Bitcoin Suisse (Europe) AG a license as a Crypto Asset Service Provider (CASP) under MiCAR. The European entity of Bitcoin Suisse can now serve clients across selected EEA markets, with Roman Przibylla appointed CEO to lead the expansion. After more than a decade as Switzerland's crypto pioneer, the Bitcoin Suisse Group ("Bitcoin Suisse") is expanding across Europe. Its European entity, Bitcoin Suisse (Europe) AG, founded in 2018, has been granted a license as a Crypto Asset Service Provider (CASP) under MiCAR by the Liechtenstein Financial Market Authority (FMA), building on its long-standing registration under the Token and TT Service Provider Act (TVTG). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260622188006/en/ left: Andrej Majcen, Co-Founder and Group CEO of the Bitcoin Suisse Group; right: Roman Przibylla, CEO of Bitcoin Suisse (Europe) AG Across Europe, Bit
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom